OVCAR-8 cells were obtained from Marcus Peter (Northwestern University, Chicago, USA, RRID: CVCL_IM65), TYK-nu cells from Gottfried Konecny (Ronald Reagan UCLA Medical Center, RRID:CVCL_1776), OVCAR-4 cells from Charles River Fredrick National Laboratory for Cancer Research (RRID:CVCL_1627), and PEO-1 cells from Scott Kaufmann (Mayo Clinic, Rochester, MN, RRID:CVCL_2686). OVCAR-8 cells were grown in DMEM (10-013-CV) (Corning) with 10% Fetal Bovine Serum (35-010-CV, FBS) (Fisher Scientific), 1% MEM nonessential amino acids (25-025-CI) (Corning) and 1% MEM Vitamins (25-020-CI) (Corning). TYK-nu cells were grown in MEM (10-022-CV) (Corning) with 10% FBS, 1% MEM nonessential amino acids (25-025-CI) (Corning) and 1% MEM Vitamins (25-020-CI) (Corning). OVCAR-4 cells were grown in RPMI with 10% Fetal Bovine Serum (35-010-CV, FBS) (Fisher Scientific). PEO-1 cells were grown in DMEM (10-013-CV) (Corning) with 10% Fetal Bovine Serum (35-010-CV, FBS) (Fisher Scientific), 1% MEM nonessential amino acids (25-025-CI) (Corning) and 1% MEM Vitamins (25-020-CI) (Corning). Cells were grown in 5% CO2 incubator at 37°C. All cells were mycoplasma negative and their identity verified regularly by short tandem repeat profiling (IDEXX) (OVCAR-8 and TYK-nu Feb 2020, OVCAR-4 June 2019, PEO-1 July 2019). Cells were passaged 2-10 times after unfreezing prior to performing experiments.
+ Open protocol